Literature DB >> 2417983

Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice.

D S Zaharko, J M Covey.   

Abstract

Arabinosyl-5-azacytosine (Ara-AC) was studied in vitro and in vivo in kinetic and therapeutic experiments. This compound is degraded fairly rapidly in mouse plasma in vitro at 37 degrees C (t 1/2 = 130 min) and even more rapidly in vivo (terminal t 1/2 = 76 mins, with a three phase plasma clearance curve, single dose iv 200 mg/kg). In vitro clonogenic assays with L1210 exposed to Ara-AC indicated that cytotoxic concentrations of 1 to 10 micrograms/ml were optimal at exposure times of 72 hours or longer (3 to 4 logs of L1210 cell kill). Extrapolating this information to in vivo infusion therapeutic studies in mice illustrated that optimal therapy (estimated 8 logs of L1210 cell kill) was also achieved at plasma concentrations of between 1 to 10 micrograms/ml for 72 hours of infusion. Infusions of 96 hours resulted in some lethal toxicity and 144 hour infusions were 100% lethal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2417983     DOI: 10.1007/bf00170753

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  5 in total

1.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

Authors:  H E SKIPPER; F M SCHABEL; W S WILCOX
Journal:  Cancer Chemother Rep       Date:  1964-02

2.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

3.  Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice.

Authors:  J M Covey; D S Zaharko
Journal:  Eur J Cancer Clin Oncol       Date:  1985-01

4.  Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor.

Authors:  D S Zaharko; J M Covey; J A Kelley
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Potential roles for preclinical pharmacology in phase I clinical trials.

Authors:  J M Collins; D S Zaharko; R L Dedrick; B A Chabner
Journal:  Cancer Treat Rep       Date:  1986-01
  5 in total
  2 in total

Review 1.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

2.  Phase I trial of a 72-h continuous-infusion schedule of fazarabine.

Authors:  R Amato; D Ho; S Schmidt; I H Krakoff; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.